Melanoma: is immunotherapy of benefit?
Faries
Mark B
MB
John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California, USA.
Morton
Donald L
DL
D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D019496:Cancer Vaccines